Buyback yield (TTM)
N/A
Shareholder yield (TTM)
2.74%
5Y share count change
-8.1%
Buyback spend (TTM)
N/A
Cumulative buybacks
$96.03B
Key takeaways
- Diluted share count is down 8.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 0% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Amgen (AMGN)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Amgen (AMGN)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Amgen (AMGN)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Amgen (AMGN)
Latest: $0.00
Overview
Amgen (AMGN) most recent annual buyback spend stands at $0.00 (2025) – plunged 100.0% year-over-year.
Amgen buyback spend has contracted on net over the period, with a -100.0% compound annual growth rate over 2020–2025 (5 years).
Amgen buyback spend plunged from $17.79B in 2018 to $0.00 in 2025, a 100.0% drawdown.
$17.79B stands as the all-time-high annual buyback spend, posted in 2018, against a low of $0.00 during 1988.
Amgen Buyback Spend 2025: $0.00
2025's buyback spend for Amgen came in at $0.00, plunged 100.0% below 2024.
Amgen Buyback Spend 2024: $200.00M
Amgen buyback spend in 2024 was $200.00M.
Amgen Buyback Spend 2023: $0.00
In 2023, Amgen reported buyback spend of $0.00, plunged 100.0% below 2022.
Amgen Buyback Spend 2022: $6.36B
Amgen buyback spend in 2022 was $6.36B, grew 27.8% from 2021.
Amgen Buyback Spend 2021: $4.97B
Amgen buyback spend in 2021 was $4.97B.
See more financial history for Amgen (AMGN).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $0.00 | $0.00 | — | 0.54B | +0.2% | |
| 2024 | $200.00M | $530.00M | −$330.00M | 0.14% | 0.54B | +0.6% | |
| 2023 | $0.00 | $431.00M | −$431.00M | — | 0.54B | -0.6% | |
| 2022 | $6.36B | $401.00M | $5.96B | 4.53% | 0.54B | -5.6% | |
| 2021 | $4.97B | $341.00M | $4.63B | 3.93% | 0.57B | -2.9% | |
| 2020 | $3.49B | $330.00M | $3.16B | 2.61% | 0.59B | -3.1% | |
| 2019 | $7.70B | $308.00M | $7.39B | 5.39% | 0.61B | -8.4% | |
| 2018 | $17.79B | $311.00M | $17.48B | 14.39% | 0.67B | -9.5% | |
| 2017 | $3.16B | $329.00M | $2.83B | 2.51% | 0.73B | -2.5% | |
| 2016 | $2.96B | $311.00M | $2.65B | 2.73% | 0.75B | -1.6% | |
| 2015 | $1.87B | $322.00M | $1.54B | 1.53% | 0.77B | -0.5% | |
| 2014 | $138.00M | $408.00M | −$270.00M | 0.11% | 0.77B | +0.7% | |
| 2013 | $832.00M | $403.00M | $429.00M | 0.97% | 0.77B | -2.8% | |
| 2012 | $4.61B | $362.00M | $4.25B | 7.00% | 0.79B | -13.7% | |
| 2011 | $8.31B | $341.00M | $7.97B | 16.37% | 0.91B | -5.5% | |
| 2010 | $3.79B | $353.00M | $3.43B | 7.39% | 0.96B | -5.5% | |
| 2009 | $3.21B | $284.00M | $2.92B | 5.77% | 1.02B | -5.0% | |
| 2008 | $2.27B | $0.00 | $2.27B | 3.81% | 1.07B | -4.3% | |
| 2007 | $5.10B | $0.00 | $5.10B | 10.08% | 1.12B | -5.6% | |
| 2006 | $2.00B | $0.00 | $2.00B | 2.51% | 1.19B | -5.4% | |
| 2005 | $4.43B | $0.00 | $4.43B | 4.67% | 1.26B | -4.7% | |
| 2004 | $4.07B | $0.00 | $4.07B | 5.08% | 1.32B | -1.9% | |
| 2003 | $1.80B | $0.00 | $1.80B | 2.28% | 1.35B | +16.7% | |
| 2002 | $1.42B | $0.00 | $1.42B | 2.28% | 1.15B | +6.4% | |
| 2001 | $737.50M | $0.00 | $737.50M | 1.25% | 1.08B | -0.0% | |
| 2000 | $799.90M | $0.00 | $799.90M | — | 1.08B | +0.6% | |
| 1999 | $1.02B | $0.00 | $1.02B | — | 1.08B | +2.0% | |
| 1998 | $912.10M | $0.00 | $912.10M | — | 1.06B | -3.7% | |
| 1997 | $737.90M | $0.00 | $737.90M | — | 1.10B | -2.2% | |
| 1996 | $450.00M | $0.00 | $450.00M | — | 1.12B | — | |
| 1995 | $285.70M | $0.00 | $285.70M | — | — | — | |
| 1994 | $300.50M | $0.00 | $300.50M | — | — | — | |
| 1993 | $207.50M | $0.00 | $207.50M | — | — | — | |
| 1992 | $85.90M | $0.00 | $85.90M | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1989 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1988 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$0.00
- 2024$200.00M
- 2023$0.00
- 2022$6.36B
- 2021$4.97B
- 2020$3.49B
- 2019$7.70B
- 2018$17.79B
- 2017$3.16B
- 2016$2.96B
- 2015$1.87B
- 2014$138.00M
- 2013$832.00M
- 2012$4.61B
- 2011$8.31B
- 2010$3.79B
- 2009$3.21B
- 2008$2.27B
- 2007$5.10B
- 2006$2.00B
- 2005$4.43B
- 2004$4.07B
- 2003$1.80B
- 2002$1.42B
- 2001$737.50M
- 2000$799.90M
- 1999$1.02B
- 1998$912.10M
- 1997$737.90M
- 1996$450.00M
- 1995$285.70M
- 1994$300.50M
- 1993$207.50M
- 1992$85.90M
- 1991$0.00
- 1990$0.00
- 1989$0.00
- 1988$0.00
Buybacks vs stock-based compensation for Amgen (AMGN)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Amgen (AMGN)
How Amgen splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Amgen, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $3.00B | |
| $980.00M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.39B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation